This company won't survive.
They turn over $30k per month, that's not enough to even pay the rent.
The product is poor and they do little too no marketing. Nothing is going to change.
See the light or loose everything.
- Forums
- ASX - By Stock
- Ann: Results of Entitlement Offer to Raise $2.21m
This company won't survive.They turn over $30k per month, that's...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ICR (ASX) to my watchlist
|
|||||
Last
1.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.364M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 900000 | 1.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.7¢ | 177503 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 900000 | 0.014 |
2 | 155769 | 0.013 |
1 | 134082 | 0.012 |
3 | 1760000 | 0.011 |
4 | 4370000 | 0.010 |
Price($) | Vol. | No. |
---|---|---|
0.017 | 177503 | 2 |
0.018 | 13000 | 1 |
0.023 | 43478 | 1 |
0.024 | 31575 | 1 |
0.025 | 478571 | 2 |
Last trade - 16.12pm 09/08/2024 (20 minute delay) ? |
Featured News
NEWS
Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo
NEWS
Is oil undervalued?
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
ICR (ASX) Chart |
Day chart unavailable